Plain-English translation of NCT07335055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can reduce inflammation and symptoms in people with moderate to severe ulcerative colitis. Ulcerative colitis is a chronic condition that causes inflammation and sores in the colon and rectum, leading to pain, diarrhea, and other uncomfortable symptoms. This study will compare the medication at two different doses against a placebo (an inactive pill) to find out if it works and is safe.
Many people with ulcerative colitis don't respond well to existing treatments or can't tolerate their side effects. Researchers are testing this medication to see if it offers a new option for patients who need better control of their symptoms.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication at one of two doses or a placebo, and neither you nor the research team will know which group you're in. You'll visit the clinic multiple times for check-ups, blood tests, and possibly colonoscopies to see how the medication is working. The study will monitor your symptoms, bowel function, and any side effects to determine whether the medication is safe and effective.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Collaborators
Haisco-USA Pharmaceuticals, Inc.
Enrollment target
~150 participants
Started
February 2026
Primary completion
October 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongrui Wang
Haisco Pharmaceutical Group Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.